Biomarker family found for chemo resistant breast cancers

April 12, 2012, University of Hull

Biomarkers which could help to predict resistance to chemotherapy in breast cancer patients have been identified by researchers from the University of Hull, UK.

The researchers found a family of proteins to be twice as prevalent in clinical samples obtained from who were resistant to chemotherapy than those who were successfully treated.

Chemotherapy resistance is a major problem for some types of and many patients undergo treatment that does not work, delaying other more suitable treatments and subjecting the patient to adverse side effects in the process.

Published online in the Journal of Proteomics, the Hull research identifies a number of potential biomarkers associated with resistance to common , including epirubicin and .

Lead researcher Dr Lynn Cawkwell, says: "A major goal in cancer research is to be able to predict the response of a patient to chemotherapy. Unfortunately, a reliable test has not yet been developed to achieve this. We hope our work can help to bring us a step closer.

"Most of my work uses clinical samples instead of cell lines, thanks to the links I have with oncologists and surgeons at Castle Hill Hospital in Hull. Studying clinical samples gives a more accurate representation of what is relevant in real-life diseases."

The project used two high-throughput processes to screen clinical samples of breast tumour tissue.

One screening method using antibodies identified 38 proteins that were twice as prevalent in samples from patients who were resistant to chemotherapy than those who were successfully treated. The other used and uncovered 57 potential biomarkers of which five belong to the 14-3-3 .

The findings from both screening methods highlight the possible importance of proteins from the 14-3-3 family and their potential for development into a predictive test for clinical use. Dr Cawkwell's team hope to investigate the protein family's role more fully in chemotherapy resistance.

"If we're correct, we hope that by testing for these proteins, doctors will be able to anticipate a patient's response to different chemotherapies, and decide which course of treatment is most appropriate for them," she says.

Dr Cawkwell's team is continuing with this study, as well as investigating radiotherapy resistance in a number of different cancers.

Explore further: Some breast cancer tumors may be resistant to a common chemotherapy treatment

More information: J Proteomics 2012 April 3 [epub ahead of print] Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer

J Proteomics. 2012 Feb 2;75(4):1276-83 Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID? Hodgkinson VC, Elfadl D, Agarwal V, Garimella V, Russell C, Long ED, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ, Cawkwell L.

Related Stories

Some breast cancer tumors may be resistant to a common chemotherapy treatment

March 27, 2012
Some breast cancer tumours may be resistant to a common chemotherapy treatment, suggests recent medical research at the University of Alberta.

Another step toward resisting breast cancer

September 21, 2011
Medical researchers at the University of Leeds have come a step closer to understanding how to stop breast cancers from coming back.

Researchers find possible key to preventing chemotherapy resistance in ovarian cancer

September 15, 2011
For patients with ovarian cancer and their physicians, resistance to chemotherapy is a serious concern. However, researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution ...

New agents show promise for treating aggressive breast cancers

July 18, 2011
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.